medigraphic.com

2001, Number 2

<< Back Next >>

Enf Infec Microbiol 2001; 21 (2)

Activity of gatifloxacin in the treatment of the respiratory tract infections

Giono CS, García ZP, Tapia NA, Peredo LVMA

Language: Spanish
References: 24
Page: 54-63
PDF size: 130.13 Kb.


ABSTRACT

Background. In Mexico the respiratory pathogens are resistant to various antimicrobials. Gatifloxacin is a new synthetic antimicrobial agent that has demonstrated good activity against different respiratory pathogens. Material and methods. As From August 1999 to January 2000 in Mexico City 201 strains have been studied out from which correspond to: 35 Haemophilus influenzae, 32 Streptococcus pneumoniae, 25 Moraxella catarrhalis, 55 Streptococcus pyogenes and 54 Staphylococcus aureus. Such strains were isolated from ambulatory and hospitalized patients with respiratory tract infections. To asses GAT activity vs other antimicrobials were tested by MIC90 with Steers replicator according to NCCLS. Results. Gatifloxacin was the antimicrobial that presented the highest susceptibility percentage towards the evaluated respiratory pathogens from 96.7-100%, ciprofloxacin 90.2-100%, ampicillin 37-94.2%, amoxicillin 48-98.2%, cephalexin 68-92.6%, cefuroxime 87.5-98.2%, cefotaxime 80-92%, ceftriaxone 84.4-100%, cefepime 87.5-100%, ceftazidime 90.6-100%, cefprozil 90.6-98.2%, imipenem 93.8-100% and amoxicillin/clavulanic acid 81.3-100%. Gatifloxacin proved to be two to ten times stronger than ciprofloxacin. Conclusions. Based on the obtained results in this study and on the previous clinical experience gatifloxacin is highly recommended in the treatment of the respiratory tract infections.


REFERENCES

  1. Giono CS. Agentes bacterianos de infecciones respiratorias: En infecciones respiratorias agudas y crónicas Eds. García ML, Giono CGS, Pacheco CR, Escobar GA, Valdespino GJL. INDRE-SS. México 1994:401-414.

  2. Ramírez JA. Introduction, challenges in the management of respiratory tract infections: a role for the new fluroquinolone, gatifloxacin introduction. J Resp Dis 1999;(suppl.20)(11):S6-S10.

  3. Neu HC. The crisis in antibiotic resistance. Science 1992;257: 1064-1072.

  4. Weinberg GA, Spitzer E, Murray P, Ghafoor A, Montgomery J, Tupasi T, Granoff. The BOSTID Haemophilus influenzae susceptibility study group. Antimicrobial susceptibility patterns of Haemophilus influenzae from children in eleven, developing nations. W.H.0. Bull. OMS 1990;68:179-184.

  5. Schimtz FJ, Krey A, Gelsel R, et al. Susceptibility of 302 MRSA isolates from 20 European University Hospitals to vancomycin and alternative antistaphylococcal compounds. Eur J Clin Microbial Infect Dis (en prensa).

  6. Barriga AG, Castillo TN, Alarcón ON, Rojas ML. Susceptibilidad in vitro de microorganismos causales de infecciones graves en pacientes hospitalizados. Rev Mex Patol Clin 1996; 43(1):43-46.

  7. Calderón E, Conde G, Gatica R, Rivera R, Hernando N, Barriga G, Hill J, Romero G. Antimicrobial resistance among bacterial isolates from children. Current Therapeutic Research 1993;54(5):482-492.

  8. Giono CS, Carrillo JL. Uso y abuso de los antibióticos. Investigación Hoy (IPN). México 1997;75:20-27.

  9. Sifuentes OJ, Donis HJ, Arredondo GJL, Escalante RO, Macías A, Muñóz JM, Ontiveros L, Novoa FO, Rodríguez SR, Rolón AL, Soriano B, Tinoco JC. Informe sobre resistencia bacteriana: Estudio piloto en seis centros de México. Rev Panam Infectol 1999; (suppl 1):S45-S47.

  10. Ramírez JA, Nguyen T, Tellier G, Coppola G, Bettis R, Dolmann A, St-Pierre C, Mayer H. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin. J Resp Dis 1999;(suppl 20) (11A):S40-S48.

  11. Ball AP, Tillotson G. Lower respiratory tract infection therapy-the role of ciprofloxacin. J Intern Med Research 23:315-327.

  12. Barriga AG, Alarcón O, Montaño de Plata C. Susceptibilidad in vitro de bacterias causales infección adquirida en la comunidad. Rev Enf Inf en Ped Mex 1997;11(42):52-58.

  13. Jacobs MR. Drug-Resistant Streptococcus pneumoniae: Rational antibiotic choices. Am J Med 1999;106(5A):19S-25S.

  14. Hosaka M, Yasue T, Fukuda H, et al. In vitro and in vivo antibacterial activities of AM-1166, a new 6-fluoro-8-methoxyquinolone. Antimicrob Agents Chemother 1992;36:2108-17.

  15. Investigator´s Brochure, Gatifloxacin (BMS-206584, Am-1155). Bristol-Myers quibb Company, Nov. 1996.

  16. Jones RN, Pfaller MA, Doern GV, Beach M. SENTRY Participant Group. Antimicrobial activity of gatifloxacin, a newer 8-methoxy fluoroquinolone, tested against over 23,000 recent clinical isolates from the SENTRY antimicrobial surveillance program, 1997. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998.

  17. NCCLS. National Committee for Clinical Laboratory Standards. Document M100-S9;19(1):63-104 NCCLS 2000 m7-A5;20(2):1-28 Wayne Penn USA 1999.

  18. Ramírez A, Molina J, Dolmann A, Fogarty C, DeAbate A, Breen J, Skuba K. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial result. J Resp Dis 1999;(suppl 20) (11):S30-S39.

  19. Melo MCN, Figuereiredo AMS, Ferreira CBT. Antimicrobial susceptibility and genome diversity among Streptococcus pyogenes strains isolated in Brazil. 40th ICAAC, Toronto, Canada ASM 2000; (Abstract 170):73.

  20. Armelagos GJ. Redes planetarias para los microbios. Mundo Científico. La Recherche en español 1999;197:57-60.

  21. Orrantia GR, Silva H, Pontani DR y el grupo de estudio Artemis para América Latina. El proyecto Artemis. Un estudio sobre la actividad de algunos antibióticos de uso común para el tratamiento de las infecciones del tracto respiratorio en diez países latinoamericanos. Rev Panam Infectol 1998;2(2):68-75.

  22. Rivera PCM. Estudio de resistencia a penicilina en cepas de Streptococcus pneumoniae de origen clínico por perfiles de PBP y PCR. Tesis de Maestría. ENCB-IPN, México 1998.

  23. Blondeau JM. A review of the comparative in vitro activities of antimicrobial agents, with a focus on five new “respiratory quinolones”. J Antimicrob Chemother 1999;43(Suppl. B):1-11.

  24. DeAbate CA, McIvor PA, McElvaine P, Skuba K, Pierce PF. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis. J Resp Dis 1999;(suppl 20) (11):S23-S29.




2020     |     www.medigraphic.com